

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 369 037 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**10.12.2003 Bulletin 2003/50**

(51) Int Cl.7: **A01N 31/14, A01N 31/04,**

**A01N 31/02, A61L 2/18**

**// (A01N31/02, 31:14, 31:04)**

(21) Application number: **03291094.5**

(22) Date of filing: **07.05.2003**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

**AL LT LV MK**

(30) Priority: **05.06.2002 DE 10224979**

(71) Applicants:

- **Air Liquide Santé (International)**  
**75341 Paris Cedex 07 (FR)**
- **SCHÜLKE & MAYR GMBH**  
**22851 Norderstedt (DE)**

(72) Inventors:

- **Beilfuss, Wolfgang**  
**22339 Hamburg (DE)**

• **Siegert, Wolfgang**

**25479 Ellerau (DE)**

• **Weber, Klaus**

**20149 Hamburg (DE)**

• **Gradtke, Ralf**

**25436 Tornesch (DE)**

• **Mohr, Michael**

**24568 Kaltenkirchen (DE)**

(74) Representative: **Conan, Philippe Claude et al**

**L'Air Liquide SA**

**Département Propriété Intellectuelle**

**75, quai d'Orsay**

**75321 Paris Cédex 07 (FR)**

(54) **Synergistic preparations based on mixtures of glycerol ether with aromatic alcohol for controlling mycobacteria**

(57) Disinfectant which has activity towards mycobacteria and comprises (a) 1-(2-ethylhexyl) glycerol ether and (b) one or more aromatic alcohols selected from the group consisting of aryloxyalkanols, oligoalkanol aryl ethers and arylalkanols.

**EP 1 369 037 A1**

## Description

**[0001]** The present invention relates to a disinfectant and the use of the disinfectant for controlling mycobacteria.

**[0002]** Mycobacteria are comparatively difficult to inactivate by biocidal active compounds. Because of their waxy cell wall they are among the most chemically resistant pathogens. Chemicals which have proved sufficiently active are phenols, aldehydes, oxidizing substances such as active oxygen compounds or halogens, and lower alcohols (such as ethanol and propanols). Thus, for example, a modern aldehyde-free disinfectant for manual disinfection of instruments comprises the following active compounds and constituents: 10 to 20% by weight of quaternary ammonium compounds, 5 to 15% by weight of phenoxypropanols, 3 to 10% by weight of aminoalkylglycines, nonionic surfactants, anticorrosion agents, pH regulators, fragrances and colourings. An aldehyde-based instrument disinfectant comprises 5 to 15% by weight of glutaraldehyde, 7 to 11% by weight of formaldehyde, 2 to 6% by weight of quaternary ammonium compound, nonionic surfactants, pH regulators, fragrances and colourings.

**[0003]** However, these known compositions are frequently aggressive towards the materials to which they are applied, for example parts made of plastic (for example seals of medical instruments) are attacked by these compositions. The use of these biocides can, in addition, on contact with human skin lead to allergies or sensitization. In particular biocides having a strongly electrophilic character (for example isothiazolones, organohalogen compounds) are increasingly becoming the subject of public debate as preservatives and disinfectants and their use is becoming restrictively regulated by legislators. On the other hand, compositions which act less aggressively to the materials or skin, are frequently not sufficiently active towards mycobacteria.

**[0004]** In addition, lower alcohols are only active when used at high concentration and, moreover, have excessive volatility. Phenols, owing to inadequate biodegradability, have a low acceptance. Active oxygen compounds such as peracetic acid are also used, but because of the pungent odour and the corrosive properties are undesirable. Aldehydes such as formaldehyde or glutaraldehyde are not acceptable owing to toxicological properties and for odour reasons. Amines such as N,N'-bis(3-aminopropyl)laurylamine give the mycobactericidal formulations containing this active compound an elevated pH which leads to an increased hazard in skin and material compatibility. Of the tuberculocidally active aromatic alcohols such as phenoxypropanols, significantly greater amounts must be used in order to achieve a corresponding action, which again leads to an increased hazard in material compatibility. Furthermore, N,N'-substituted glycine derivatives have been described as mycobactericidal active compounds (see DE-A-19801821), but these active compounds have a tendency to develop foam, which is undesirable for many applications.

**[0005]** There is therefore a desire for mycobacteria-controlling compositions which do not have the said disadvantages, or do not have the disadvantages to this extent, and are more compatible for humans (especially human skin) and environment. The compositions are to successfully inactivate mycobacteria and are not to act aggressively towards the materials to which they are applied.

**[0006]** The use of glycerol monoalkyl ethers in dermatological compositions is known.

**[0007]** DE-C-42 40 674 discloses that glycerol monoalkyl ethers of the formula  $R-O-CH_2-CHOH-CH_2OH$  have a deodorizing action. Moreover, a combination of 0.15% by weight of phenoxyethanol with 0.135% by weight of 1-(2-ethylhexyl) glycerol ether is described which comprises, in addition, 40% by weight of ethanol and 0.015% of dibromodicyanobutane.

**[0008]** DE-A-40 26 756 relates to preservatives which comprise, as synergistic active compounds, a mixture of a) an organic acid, b) a monophenyl glycol ether and c) a guanidine derivative. Examples 13 and 14 are concentrates containing more than 60% by weight of phenoxyethanol and 15 and 10% by weight, respectively, of glycerol monoalkyl ether. The preservatives of DE-40 26 756 are active against various bacteria and yeasts.

**[0009]** DE-C-41 40 473 discloses compositions usable as skin antiseptics and hand disinfectants, which compositions comprise a combination of an aliphatic  $C_1$ - to  $C_6$ -alkylalcohol component and at least one glycerol monoalkyl ether in aqueous solution. A preferred glycerol ether is 1-(2-ethylhexyl) glycerol ether (Sensiva SC 50).

**[0010]** DE-A-41 24 664 describes antimicrobially active mixtures which comprise a synergistic combination of aryl-substituted alkanol with diol. Examples of diols are glycerol monoalkyl ethers.

**[0011]** DE-A-100 25 124 discloses formulations having a content of a combination of glycerol monoalkyl ether with aryl-substituted alcohol. A preferred aryl compound is phenoxyethanol.

**[0012]** An object underlying the present invention is to provide a disinfectant having activity towards mycobacteria, which disinfectant, in particular,

? does not attack, or does not attack markedly, materials which are used in the hospital sector and must be disinfected and

? in contact with the human skin does not have an irritating activity and does not have a degreasing activity (that is to say does not obligatorily have a high content of lower alcohols such as ethanol or isopropanol).

**[0013]** This object is achieved by a disinfectant which comprises (a) one or more 1- or 2-(C<sub>3</sub>- to C<sub>24</sub>-alkyl) glycerol ethers and (b) one or more aromatic alcohols.

**[0014]** Examples of inventively used glycerol monoalkyl ethers are glycerol monoalkyl ethers substituted in the 1 or 2 position (that is to say symmetrically or asymmetrically) with saturated or unsaturated, branched or unbranched alkyl such as dodecyl glycerol ether, decyl glycerol ether, octyl glycerol ether, propyl glycerol ether, octadecyl glycerol ether (batyl alcohol), hexadecyl glycerol ether (chimyl alcohol) and octadecenyl glycerol ether (selachyl alcohol). Preference is given to 1-monoalkyl glycerol ethers having a saturated (branched or unbranched) C<sub>3</sub> to C<sub>18</sub>-alkyl, particular preference is given to saturated and branched C<sub>6</sub>- to C<sub>12</sub>-alkyl. Very particular preference is given to 1-(2-ethylhexyl) glycerol ether (Sensiva® SC 50).

**[0015]** Aromatic alcohols are selected from aryloxyalkanols (glycol monoaryl ethers), oligoalkanol aryl ethers and arylalkanols.

**[0016]** Aryloxyalkanols used according to the invention have the formula AR-O-(CHR)<sub>n</sub>-OH where R = independently H (for n ≥ 2) or C<sub>1</sub>- to C<sub>6</sub>-alkyl, where n is an integer and is preferably 2 to 10, more preferably 2 to 6, and in particular 2 or 3. Whereas the group Ar can be a nuclear-substituted or unsubstituted aryl group, unsubstituted aryl, for example phenyl or naphthyl, is preferred. Examples of inventively used aryloxyalkanols are phenoxyethanol and phenoxypropanols. Preferred phenoxypropanols are 1-phenoxypropan-2-ol, 2-phenoxypropan-1-ol or mixtures thereof, and also 3-phenoxypropan-1-ol. Oligoalkanol aryl ethers include, for example phenoxydiethanol, phenoxytriethanol and phenoxyoligoethanol and phenoxydipropanol, phenoxytripropanol and phenoxyoligopropanol.

**[0017]** Arylalkanols used according to the invention have the formula Ar-(CHR)<sub>n</sub>-OH where R = independently H or C<sub>1</sub>- to C<sub>6</sub>-alkyl, where n is an integer and is preferably 1 to 10, more preferably 1 to 6 and in particular 1, 2, 3 or 4. While the group Ar can be a nuclear-substituted or unsubstituted aryl group, unsubstituted aryl, e.g. phenyl or naphthyl, is preferred. Examples of arylalkanols are 3-phenylpropan-1-ol, phenylethyl alcohol, veratryl alcohol (3,4-dimethoxyphenylmethyl alcohol), benzyl alcohol and 2-methyl-1-phenyl-2-propanol.

**[0018]** In one embodiment, the weight ratio x of component (a) to component (b) in the inventive disinfectant is 0.15 or less, preferably 0.09 or less, more preferably 0.08 to 0.03, and in particular 0.07 to 0.04.

**[0019]** In a further embodiment according to the invention, the disinfectant is present in the form of a working mixture and comprises a relatively small amount of components (a) and (b), e.g. (a) 0.05 to 1% by weight of one or more glycerol monoalkyl ethers, e.g. 1-(2-ethylhexyl) glycerol ether, and (b) 0.2 to 5% by weight of one or more aromatic alcohols such as glycol monoaryl ether. One example of a working mixture is a working solution. A preferred working solution is present as an aqueous solution and comprises more than 95% by weight of water, e.g. 96 to 99.5% by weight, more preferably 97 to 99% by weight, in particular 98 to 98.5% by weight of water. Particular preference is given to a working solution which comprises (a) 0.05 to 0.2% by weight of 1-(2-ethylhexyl) glycerol ether and (b) 1.0 to 2.0% by weight of phenoxyethanol. Alternatively, the working mixture can be present in solid, pasty or high-viscosity form.

**[0020]** In a further embodiment of the invention the disinfectant is present as concentrate and comprises relatively high amounts of components (a) and (b). Because a preferred concentrate is a single-phase concentrate which may be formulated particularly easily with other components to give a working mixture, a preferred inventive concentrate is present in anhydrous form, because of the limited water solubility of components (a) and (b) (Sensiva SC 50 is soluble in water at room temperature up to 0.1% by weight, phenoxyethanol, for example, is soluble in water at room temperature up to 1.8% by weight).

**[0021]** In addition to the inventive components (a) and (b) the disinfectant can comprise other components. Preferably, however, it is low in surfactants and comprises less than 5% by weight of surfactant, preferably less than 2% by weight, particularly preferably less than 0.5% by weight of surfactant and especially preferably is surfactant free. The further components can be solid, liquid or gaseous other active compounds, functional additives or aids.

**[0022]** Because of the particular physiological compatibility, inventive disinfectants have a broad field of application. They can be clear, homogeneous, e.g. aqueous formulations, or can be low-viscosity or high-viscosity formulations, for example gels. The disinfectants are active over a broad pH range and are usable in strongly acidic to strongly alkaline media, preferably in the pH range from 3 to 11, particularly preferably 5 to 9.

**[0023]** Examples of compositions designated here as disinfectants are:

1) technical products such as biocide dispersions, dispersions in the agricultural sector, pesticide formulations, polymer dispersions, adhesives, thickeners, dyes, coating materials, pigment dispersions, photographic materials (for example developer solutions),

2) dermatological and cosmetic products, for example for topical application or as leave-on or rinse-off products such as sun protection preparations, moist cloths, polymer formulations having film-forming properties, tooth-pastes, care products, makeup, lipsticks, nail polish,

3) pharmaceutical preparations such as isotonic solutions, drugs and vaccines and

4) disinfectant preparations such as deodorants, foot deodorants, alcoholic spray disinfectants and compositions for manual instrument cleaning.

**[0024]** Surfaces with which inventive disinfectants can be treated are :

i) biological materials such as skin, mucous membrane, wounds, plants, plant parts,

ii) materials which come into contact with skin, mucous membrane or wounds, such as contact lenses or wound dressings,

iii) surfaces such as medical equipment, medical instruments (for example endoscopes) or surfaces such as floors and operation benches.

**[0025]** A further inventive embodiment relates to a process for treating the said surfaces, in particular for controlling mycobacteria. For this the inventive disinfectant is allowed to act on the surface to be disinfected. The inventive disinfection process is used in particular in the disinfection of medical instruments or laboratory equipment, in which case the surfaces to be disinfected can be fabricated from metal, glass, plastic or ceramics.

**[0026]** The inventive disinfection process can be reinforced by ultrasound, pressure or microwave radiation. Those skilled in the art will select here an optimum between the parameters time of action and concentration of the components (a) and (b) which corresponds to the desired microbicidal action, depending on the sensitivity of the material to be disinfected.

**[0027]** The inventive disinfectants can have activity towards bacteria (Gram-positive) and (Gram-negative), yeasts and moulds, mycobacteria and viruses. Thus, they are, for example, active towards propionibacteria (*Propionibacterium acnes*), dandruff-causing microorganisms, prions, antibiotic-resistant microorganisms, enveloped and/or nonenveloped viruses, odour-causing microorganisms, lower pathogens, protozoa and spores.

**[0028]** The present invention offers, inter alia, the following advantages:

- The disinfectants can be formulated from inexpensive components.
- The disinfectants are pH neutral, scarcely aggressive (low corrosion) and correspondingly readily material-compatible.
- The agents are low-odour, low-emission, inert and readily compatible with other additives or aids, toxicologically and ecotoxicologically harmless, physiologically harmless (good skin compatibility), of high keeping quality and easily washed off.
- The agents show no tendency to discoloration, are active in short times of action and, owing to the synergistic increase in activity, require a low concentration of active compound.
- The agents are low-foaming and oxidation- and pH-stable.

**[0029]** The advantages of the invention are given in particular by the following examples.

#### Examples

**[0030]** The following abbreviations are used:

SC 50 1-(2-ethylhexyl) glycerol ether Sensiva SC 50

Water demineralized water

Ethanol ethanol, denatured with methyl ethyl ketone

POE phenoxyethanol

**[0031]** Unless explicitly stated otherwise, all percentages are per cent by weight.

**Example 1: Activity of disinfectants towards *Mycobacterium terrae* at room temperature**

[0032] Various aqueous disinfectants were tested with respect to their activity towards *Mycobacterium terrae*, cell count  $1$  to  $3 \times 10^9$  in a quantitative suspension test without load. The following reduction factors were measured, a reduction factor  $> 5$  corresponding to a sufficient Tb activity. For this various amounts of ethanol were added to aqueous active compound solutions and after exposure for 15, 30 and 60 minutes were tested. For testing the tuberculocidal activity, the quantitative suspension test *Mycobacterium terrae* (ATCC15755) was used in accordance with the Deutsche Gesellschaft für Hygiene und Mikrobiologie [German Society for Hygiene and Microbiology] of 30 April 1997 (Hyg. Med. 22, 1997, issue 6, pages 278ff.).

Comp.	Comp. without ethanol content			10% EtOH			20% EtOH			30% EtOH		
	15'	30'	60'	15'	30'	60'	15'	30'	60'	15'	30'	60'
A	0	0	0	0	0	0	0	0	0	0.83	2.78	4.65
B	0	0	0	0	0	0	0	0	0.66	2.02	4.02	5.52
C	0	0	0	0	1.92	2.98	3.67	6.14	5.36	5.49	6.14	5.36
D	2.94	5.41	5.52	4.66	5.41	5.52	5.36	5.41	5.52	5.36	5.41	5.52
A) water												
B) 0.1% SC 50 in water												
C) 1.5% POE in water												
D) 0.1% SC 50 + 1.5% POE in water												

**Result:**

[0033] Tests with *Mycobacterium tuberculosis* were not carried out because of the hazardousness of the tuberculosis bacterium. Owing to the strong structural similarity of *Mycobacterium terrae* with *Mycobacterium tuberculosis*, however, the results above permit the activity tests with *Mycobacterium terrae* to provide information on the activity towards *Mycobacterium tuberculosis*.

[0034] Aqueous ethanol, even at a content of 30%, is not sufficiently Tb active. By adding 0.1% glycerol monoalkyl ether Sensiva SC 50, 30% strength ethanol is sufficiently Tb active at an exposure time of 60 minutes. By adding 1.5% glycol monoaryl ether POE, 20% ethanol at an exposure time of 30 minutes is sufficiently Tb active. In contrast, an inventive combination of 0.1% Sensiva SC 50 with 1.5% POE is Tb active at room temperature at an exposure time of 30 minutes even without ethanol addition.

[0035] Inventive aqueous working solutions are sufficiently active even at low contents of components (a) and (b). In addition, inventive compositions, for activity towards mycobacteria, do not require a comparatively high amount of ethanol which is undesirable, inter alia, because of the associated corrosive action towards various materials and the extractive action in the case of exposure to hands, for example.

**Example 2: Activity of disinfectants in the Koko test**

[0036] The following aqueous working solutions were examined using Ringer solution as product in the Koko test:

**Analytical principle**

[0037] Using the method described, the activity of chemical preservatives is tested with respect to package preservation for cosmetics formulations. For this, in various experimental batches, the preservatives under test at various concentrations are added to the non-preserved samples. A continuous microbial load is achieved by periodic inoculation of the experimental batches. In parallel to the inoculation, in each case immediately before, streak samples of the individual batches were taken. Evaluation is made on the basis of microbial growth of the streak samples. A preservative is more effective, the longer the period to the first appearance of microbial growth.

**Solutions and nutrient media****[0038]**

CSA (caseine peptone - soya bean peptone agar)

## EP 1 369 037 A1

SA (Sabouraud dextrose agar)  
 SA slope tubes  
 CSA + TLSH (No. 4)  
 SA-TLSH (No. 10)  
 NaCl (physiological common salt solution, 8.5%)

**[0039]** The test organism used was the mixed suspension (group 5) of the following four test organism groups.

Group 1 (Koko 1)	Staphylococcus aureus	ATCC 6538
	Staphylococcus epidermis	ATCC 12228
Group 2 (Koko 2)	Enterobacter gergoviae	Dr Eigner/ Beiersdorf company 1994
	Escherichia coli	ATCC 11229
	Klebsiella pneumoniae	ATCC 4532
Group 3 (Koko 3)	Pseudomonas aeruginosa	ATCC 15442
	Pseudomonas fluorescens	ATCC 17397
	Pseudomonas purida	ATCC 12633
Group 4 (Koko 4)	Aspergillus niger	ATCC 6275
	Penicillium funiculosum	ATCC 36839
	Candida albicans	ATCC 10231

### Growth of test organisms

**[0040]** Bacteria: streak with sterile glass rod on CS agar

Yeasts: streak with sterile glass rod on SA agar

Fungi: Aspergillus niger is transferred to 4Sa-slope tubes

Penicillium funiculosum is transferred to Sa agar plates

**[0041]** All test organisms are incubated for one week at  $25^{\circ}\text{C} \pm 2^{\circ}\text{C}$ . The test organisms are renewed at intervals of 3 to 4 months.

### Preparation of the inoculation solution (groups 1 to 3)

**[0042]** The bacteria are suspended in each case with 5 ml of NaCl solution, filtered through a glass funnel containing glass wool into a 100 ml measuring cylinder and made up to 100 ml with NaCl. The bacterial suspensions have a titre of approximately  $10^9$  CFU/ml.

### Preparation of the inoculation solution (group 4)

**[0043]** Three Aspergillus niger slope tubes are shaken each with 3 ml of NaCl solution on the Heldolph stirrer and passed through a glass funnel containing glass wool. The yeast Candida albicans is suspended with 5 ml of NaCl and also poured through the glass funnel. 5 ml of a Penicillium funiculosum suspension (see analytical procedure No. 22 for preparation of the fungal suspension) is added to this mixture and the mixture is made up to 100 ml with NaCl. The fungal suspension has a titre of approximately  $10^{5-9}$  CFU/ml.

### Preparation of the inoculation solution (group 5)

**[0044]** The inoculation solution actually used is prepared as described above (groups 1 to 4). After the suspension this is mixed and only then made up to 100 ml with NaCl.

**[0045]** The microbial suspensions are transferred to sterile glass-stoppered flasks containing glass beads and shaken for 5 min at a shaking frequency of 200 units/minute (to-and-fro motion). The microbial content of the mixed suspensions is at around  $10^9$  CFU/ml. The suspension should be used on the day of preparation, but if stored in a refrigerator, can also be used after 24 hours.

Procedure

[0046] In separate batches, in each case 25 g of the cosmetic under test is admixed with the preservatives under test at differing concentrations. A non-preserved product sample serves in each case as growth control. The test batches are streaked onto CSA/TLSH and Sa/TLSH using a sterile glass rod after thorough stirring once a week, the first streak being carried out immediately before the new inoculation. All samples are inoculated with 0.1 ml of the respective microbial suspension and stirred thoroughly.

[0047] The microbial growth of the streak samples is evaluated after incubation for three days at  $25^{\circ}\text{C} \pm 2^{\circ}\text{C}$ . Negative streak samples, for a safety margin, are observed for a further 2 days and again evaluated. The preservative activity of the individual product concentration is evaluated in semiquantitative method via growth of the individual streak samples.

[0048] The test is usually carried out over six inoculation cycles and interrupted after solid overgrowth has occurred twice.

Evaluation of the results

[0049] A preservative is to be considered good if, under the laboratory conditions above, there is a period of 6 weeks without microbial infection of the test batches, that is to say even after the sixth inoculation no microbial growth is detectable.

	Inoculation cycles withstood
0.1% SC 50	0
1.0% POE	1
0.1% SC 50 + 1.0% POE	> 6

Result:

[0050] Inventive disinfectants show in the Koko test a synergistic action of components (a) and (b).

**Example 3: Increase in activity of inventive disinfectants towards *B. subtilis* by addition of  $\text{H}_2\text{O}_2$** 

[0051] The following disinfectants were formulated:

	3A	3B	3C	3D	3E	3F
SC 50	0.1	0.1	0.1	0.1		0.1
POE	1.5	1.56	1.5	1.5		1.5
$\text{H}_2\text{O}_2$ 30%	16.7	13.3	10.0	6.7	16.7	
Water	81.7	85.1	88.4	91.7	83.3	98.4

[0052] With these disinfectants, the following reduction factors were obtained with *B. subtilis*. In this case the procedure is carried out on the basis of DIN draft EN14347 "sporicidal action (base test)" of February 2002, see, in particular, point 5.5.2.2.1 there.

Comp.	Dilution with water	Exposure time						% $\text{H}_2\text{O}_2$ A.I.
		15'	30'	60'	2h	4h	6h	
3A	not diluted	0.22	0.29	0.45	0.54	4.70	4.78	5%
3B	not diluted	0.14	0.15	0.25	0.50	0.81	4.78	4%
3C	not diluted	0.23	0.20	0.31	0.47	0.51	2.99	3%
3D	not diluted	0.28	0.26	0.34	0.41	0.42	0.76	2%
3E	not diluted	0.29	0.30	0.40	0.49	1.66	4.78	5%
3F	not diluted	0	0	0	0	0.37	0.19	

**Result:**

[0053] The spore activity of inventive disinfectants can be increased by adding H<sub>2</sub>O<sub>2</sub>.

5 **Example 4: Activity of disinfectants towards bacteria and yeast fungi**

[0054] The following three formulations were examined with respect to their activity:

- 10 4A 0.1% SC 50 in water  
 4B 1.5% POE in water  
 4C 0.1% SC 50 + 1.5% POE in water

15 [0055] Using these formulations the following reduction factors were obtained (SA = *Staphylococcus aureus*, PS = *Pseudomonas aeruginosa*, EC = *Escherichia coli*, PM = *Proteus merabilis* and CA = *Candida albicans*), in which case 50% and 25% dilutions with water were also studied (initial cell count 0.8-5 x 10<sup>9</sup>/ml, at CA 2 x 10<sup>7</sup>/ml, de-inhibition Tryp-NaCl-TLSH (No. 22).

Method:

20 [0056] 0.1 ml of the microbial suspension in CSL is mixed thoroughly at room temperature with 10 ml of the disinfectant dilution under test (in water of standardized hardness, WSH). After exposure times of 5, 15, 30 and 60 minutes, in each case 1 ml is taken off from the disinfectant/microbial mixture and inoculated into 9 ml of inactivation liquid (0.1% tryptone + 0.85% NaCl in twice-distilled water + inactivation substances). After at most 30 minutes contact time in inactivation liquid, dilutions (10<sup>-2</sup> and 10<sup>-4</sup> in 0.1% tryptone + 0.85% NaCl in twice-distilled water) are made up. Then,  
 25 0.1 ml each of the inactivation liquid and the two dilutions are spread onto 3 CSA plates each. As a control the respective solid microbial suspension is mixed with 10 ml of WSH, instead of disinfectant. In parallel to the corresponding exposure times, subcultures are to be made up from this batch in the same manner.

30 [0057] All subcultures are incubated for 48 hours at 37°C, in the case of *Candida albicans* for 72 hours at 37°C, and the colonies are counted. The reduction is calculated in the following manner: KWEs between 20 and 300 per CSA plate are to be evaluated. After determining the arithmetic mean of three values, the disinfectant action (KR<sub>t</sub>) per unit time is calculated from the formula  $KR_t = \log_{CFU(co)} \text{ minus } \log_{CFU(D)}$ , where (CFU(co) is the number of CFUs per ml without action of the preparation and CFU(D) is the number of CFUs per ml after action of the preparation.

4A Starting concentration	SA				PS			
	5'	15'	30'	60'	5'	15'	30'	60'
100%	0	0	0	0	0	0	0	0
50%	0	0	0	0	0	0	0	0
25%	0	0	0	0	0	0	0	0
	EC				PM			
	5'	15'	30'	60'	5'	15'	30'	60'
100%	0	0	0	0	0	0	0	0
50%	0	0	0	0	0	0	0	0
25%	0	0	0	0	0	0	0	0
	CA							
	5'	15'	30'	60'				
100%	0	0.59	0.05	0.22				
50%	0	0.41	0.07	0				
25%	0	0.19	0	0				
4B Starting concentration	SA				PS			
	5'	15'	30'	60'	5'	15'	30'	60'
100%	0	0	0	1.12	1.74	5.38	5.26	5.46
50%	0	0	0	0	0	0	0	0
25%	0	0	0	0	0	0	0	0



(continued)

	EC				PM			
100%	2.53	4.70	5.15	5.15	5.04	4.90	5.18	5.11
50%	0	0	0	0	0	0	0	0
25%	0	0	0	0	0	0	0	0
	CA							
100%	0.43	0.45	0.35	0.33				
50%	0.13	0.38	0.35	0.33				
25%	0	0.29	0.35	0.22				
4C Starting concentration	SA				PS			
	5'	15'	30'	60'	5'	15'	30'	60'
100%	3.30	3.55	4.20	4.70	5.81	5.38	5.26	5.46
50%	0	0	0	0	0	0	0	0
25%	0	0	0	0	0	0	0	0
	EC				PM			
100%	5.00	4.70	5.15	5.15	5.04	4.90	5.18	5.11
50%	0	0	0	0	0	0	0	0
25%	0	0	0	0	0	0	0	0
	CA							
100%	1.85	3.49	3.30	3.18				
50%	0.07	0.13	0.35	1.18				
25%	0.16	0	0.52	0.27				

[0058] Result: these data show a partial synergistic action of the combination of SC 50 with POE.

#### Example 5: Activity of disinfectants towards *Micrococcus luteus* in the skin test

[0059] The following ethanol-containing disinfectants were formulated. The test method used was the "Richtlinie für die Prüfung und die Bewertung von Hautdesinfektionsmitteln" [Guideline for testing and evaluation of skin disinfectants] of the Deutsche Gesellschaft für Hygiene und Mikrobiologie of 1 January 1991, see Zbl. Hyg. 192, pages 99-103 (1991).

	5A	5B	5C	5D	5E*
Ethanol	35.0	35.0	35.0	35.0	
SC 50		1.0		0.5	
POE			1.0	0.5	
Water	65.0	64.0	64.0	64.0	30
Isopropanol					70

\* reference solution as in DGHM guidelines for testing and evaluation of skin disinfectants

[0060] The following reduction factors were obtained:

Exposure time					
30 seconds	0.68	2.36	1.55	2.83	2.11
1 minute	0.75	2.86	1.95	3.21	2.30
2 minutes	1.25	3.35	1.77	3.66	2.37

**Result:**

[0061] Compared with the reference solution, the inventive composition shows an improved activity, the inventive

working solution (5D) comprising 64% or water, compared with the reference solution comprising only 30% water. The inventive formulation is thus much more compatible for the skin. From the comparison with the formulation 5B not according to the invention, it was found that by combination with POE, a portion of the comparatively expensive SC 50 can be replaced and this combination even results in an improvement in activity.

## Claims

1. Disinfectant in the form of a working mixture which comprises

(a) 0.05 to 1% by weight of 1-(2-ethylhexyl) glycerol ether and

(b) 0.2 to 5% by weight of one or more aromatic alcohols selected from the group consisting of aryloxyalkanols, oligoalkanol aryl ethers and arylalkanols.

2. Disinfectant in the form of a working mixture or of a concentrate, **characterized in that** it comprises

(a) 1-(2-ethylhexyl) glycerol ether and

(b) one or more aromatic alcohols selected from the group consisting of aryloxyalkanols, oligoalkanol aryl ethers and arylalkanols,

the weight ratio x of component (a) to component (b) being 0.15 or less.

3. Disinfectant according to Claim 1 or Claim 2, **characterized in that** the weight ratio x of component (a) to component (b) is 0.09 or less, more preferably 0.08 to 0.03, in particular 0.07 to 0.04.

4. Disinfectant according to one of the preceding claims, **characterized in that** the aryloxyalkanol is phenoxyethanol or phenoxypropanol.

5. Disinfectant according to one of the preceding claims, **characterized in that** the arylalkanol is 3-phenylpropan-1-ol, phenylethyl alcohol, veratryl alcohol, benzyl alcohol or 2-methyl-1-phenyl-2-propanol.

6. Disinfectant in the form of a working mixture which comprises

(a) 0.05 to 0.2% by weight of 1-(2-ethylhexyl) glycerol ether and

(b) 1.0 to 2.0% by weight of phenoxyethanol.

7. Disinfectant according to one of the preceding claims, **characterized in that**, in addition, it comprises water, ethanol and/or H<sub>2</sub>O<sub>2</sub>.

8. Use of a disinfectant which comprises (a) one or more 1- or 2-(C<sub>3</sub>- to C<sub>24</sub>-alkyl) glycerol ethers and (b) one or more aromatic alcohols for controlling mycobacteria.

9. Use according to Claim 8, **characterized in that** the mycobacterium is selected from the group consisting of *Mycobacterium leprae*, *Mycobacterium tuberculosis* and *Mycobacterium terrae*.

10. Use according to Claim 8 or 9, **characterized in that** a disinfectant according to one of Claims 1 to 7 is used.

11. Process for controlling mycobacteria in which a disinfectant which comprises (a) one or more 1- or 2-(C<sub>3</sub>- to C<sub>24</sub>-alkyl) glycerol ethers and (b) one or more aromatic alcohols is allowed to act on the surface to be disinfected.

12. Process according to Claim 11, **characterized in that** the surface to be disinfected is a medical instrument or laboratory apparatus or a biological surface, in particular skin, mucosal membrane, wounds, plants or plant parts.

13. Process according to Claim 11 or 12, **characterized in that** the surface to be disinfected is fabricated from metal, glass, plastic or ceramics.

**EP 1 369 037 A1**

14. Process according to one of Claims 11 to 13, **characterized in that** the disinfectant is a disinfectant according to one of Claims 1 to 7.

5

10

15

20

25

30

35

40

45

50

55



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 03 29 1094

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,A	EP 1 157 687 A (BEIERSDORF AG) 28 November 2001 (2001-11-28) * paragraphs [0005] - [0010], [0057] - [0060], [0062] - [0067], [0070], [0073] - [0075], [0081] *	1-14	A01N31/14 A01N31/04 A01N31/02 A61L2/18 //(A01N31/02, 31:14,31:04)
D,A	EP 0 599 433 A (SCHUELKE & MAYR GMBH) 1 June 1994 (1994-06-01) * page 2, line 28-53 * * page 4, line 19-21 * 'Deo B' in Table on page 8.	1-14	
A	EP 0 551 975 A (SCHUELKE & MAYR GMBH) 21 July 1993 (1993-07-21) * page 2, line 3-10,36-45 * * page 3, line 16-34 *	1-14	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A01N A61L
Place of search	Date of completion of the search	Examiner	
MUNICH	24 July 2003	Klaver, J	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P/C/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 29 1094

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

24-07-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1157687 A	28-11-2001	DE 10025124 A1	22-11-2001
		EP 1157687 A2	28-11-2001
EP 0599433 A	01-06-1994	DE 4240674 C1	24-03-1994
		AT 161712 T	15-01-1998
		DE 59307938 D1	12-02-1998
		EP 0599433 A1	01-06-1994
		ES 2111711 T3	16-03-1998
		US 5516510 A	14-05-1996
EP 0551975 A	21-07-1993	DE 4201038 A1	22-07-1993
		AT 155319 T	15-08-1997
		DE 59306899 D1	21-08-1997
		EP 0551975 A1	21-07-1993
		ES 2105091 T3	16-10-1997
		US 5393789 A	28-02-1995

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**THIS PAGE BLANK (USPTO)**